Based on these premises, a phase 1–3, randomized, placebo‐controlled study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of the mentioned anti‐FUS ASO in FUS‐ALS is currently ongoing in many ALS centers in America, Europe, and Asia (ClinicalTrials.gov Identifier: NCT04768972). This evidence concerns the gene FUS and amyotrophic lateral sclerosis.